Saxenda vs Wegovy 2026: Which Weight Loss Injection Actually

Saxenda and Wegovy are both injectable GLP-1 medications for weight loss — but they’re not the same drug. If you’re deciding between them (or wondering why your doctor recommends one over the other), here’s the complete comparison.

Saxenda vs Wegovy: The Key Difference Upfront

The most important thing to know: Saxenda and Wegovy work through the same GLP-1 mechanism, but they contain different drugs and have significantly different effectiveness. Wegovy produces roughly twice the weight loss of Saxenda in clinical trials.

Head-to-Head Comparison

	Saxenda	Wegovy
Active ingredient	Liraglutide	Semaglutide
Injection frequency	Daily	Weekly
Max dose	3.0 mg/day	2.4 mg/week
Average weight loss (trials)	~8% body weight (SCALE trial)	~15% body weight (STEP trial)
FDA approval	Chronic weight management (BMI ≥30 or ≥27 + comorbidity)	Chronic weight management (same criteria)
Approved age	12+ years (pediatric approval)	12+ years (pediatric approval)
Cardiovascular benefit	Shown in LEADER trial (T2D patients)	Shown in SELECT trial (broader population)
Monthly cost (retail)	~$1,300–$1,500	~$1,000–$1,400
Injection device	Multi-dose pen, daily	Single-dose auto-injector, weekly
Dose escalation	6 weeks to full dose	16 weeks to full dose

Why Wegovy Works Better

Both drugs are GLP-1 receptor agonists, but semaglutide (Wegovy) has a much longer half-life than liraglutide (Saxenda). This allows weekly instead of daily dosing — and more importantly, allows for higher sustained receptor activation that produces meaningfully greater appetite suppression and weight loss.

In SCALE trials, liraglutide produced average weight loss of about 8% of body weight over 56 weeks. In STEP trials, semaglutide produced 15–17% over 68 weeks. Head-to-head, the gap is significant and consistent across multiple analyses.

Who Saxenda Still Makes Sense For

Situation	Verdict
Insurance covers Saxenda but not Wegovy	Saxenda is reasonable — better than nothing
Children/adolescents aged 12–17	Both are approved; discuss with pediatric endocrinologist
Didn’t tolerate semaglutide’s side effects	Saxenda may be better tolerated for some patients
Primary goal is significant long-term weight loss	Wegovy strongly preferred
Cost is equal and no insurance	Wegovy or compounded semaglutide preferred

Side Effect Comparison

Both drugs share the same GLP-1 side effect profile — nausea, vomiting, diarrhea, constipation, and decreased appetite. However, there are practical differences:

• Saxenda: Daily injections mean daily exposure to peak drug levels, which some patients find means more consistent low-grade nausea throughout the week. Missing doses is more disruptive.
• Wegovy: Weekly injection means nausea tends to cluster around 1–3 days post-injection with relative relief the rest of the week. Dose escalation is slower (16 weeks vs 6 weeks), which many patients find easier to tolerate.

Saxenda is sometimes considered by prescribers for patients who had very severe nausea on semaglutide — liraglutide’s different kinetics can occasionally produce a more tolerable side effect pattern for specific individuals.

The Compounded Semaglutide Factor

One major shift in 2024–2025: compounded semaglutide became widely available at $150–$350/month — dramatically cheaper than both brand Wegovy and Saxenda. For patients without insurance coverage, compounded semaglutide now dominates the cost-effectiveness calculation, making Saxenda much harder to recommend at its retail price of $1,300–$1,500/month.

There is no equivalent compounded liraglutide market, so Saxenda doesn’t have the same price-disrupting alternative. This is a meaningful practical advantage for semaglutide access.

Frequently Asked Questions

Is Saxenda or Wegovy better for weight loss?

Wegovy produces approximately twice the weight loss of Saxenda in clinical trials (~15% vs ~8% of body weight). For most patients whose primary goal is significant weight loss, Wegovy is the superior choice. Saxenda may make sense if insurance covers it when Wegovy isn’t covered, or if a patient had specific tolerability issues with semaglutide.

Why would a doctor prescribe Saxenda instead of Wegovy?

The most common reason is insurance coverage — some plans cover Saxenda but not Wegovy. Saxenda was approved earlier (2014 vs Wegovy’s 2021) and has better formulary placement on some older insurance plans. Additionally, for patients who have tried semaglutide and couldn’t tolerate it, liraglutide’s different pharmacokinetic profile is worth trying.

Can you switch from Saxenda to Wegovy?

Yes, and many patients who switch report significantly better results. The switch is typically done by stopping Saxenda and starting Wegovy at the initial low dose (0.25 mg), then escalating normally. There’s no required washout period. Talk to your prescriber about the transition if you’re interested in switching.